{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&_page=0&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1000233", "AnsweringBody" : [{"_value" : "Treasury"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1000233/answer", "answerText" : {"_value" : "<p>I refer the Honourable member to my statement made on 5<sup>th<\/sup> November 2018, to Parliamentary Question 186276:<\/p><p><a href=\"https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2018-10-31/186276/\" target=\"_blank\">https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2018-10-31/186276/<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3935", "label" : {"_value" : "Biography information for Mel Stride"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Devon"}
        , "answeringMemberPrinted" : {"_value" : "Mel Stride"}
        , "dateOfAnswer" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-12T10:27:47.36Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "14"}
      , "answeringDeptShortName" : {"_value" : "Treasury"}
      , "answeringDeptSortName" : {"_value" : "Treasury"}
      , "date" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Locums: Tax Avoidance"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Chancellor of the Exchequer, what estimate his Department has made of the effect on locum doctors and nurses of the 2019 loan charge for disguised remuneration schemes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "187296"}
    , {"_about" : "http://data.parliament.uk/resources/999385", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/999385/answer", "answerText" : {"_value" : "<p>This Government is committed to ensuring patients have access to the medicines they need and that they are cost-effective and affordable to the NHS.<\/p><p> <\/p><p>The Intellectual Property Office has no role in the negotiating and setting of drug prices which is the responsibility of the Department for Health and Social Care.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3980", "label" : {"_value" : "Biography information for Mr Sam Gyimah"}
        }
        , "answeringMemberConstituency" : {"_value" : "East Surrey"}
        , "answeringMemberPrinted" : {"_value" : "Mr Sam Gyimah"}
        , "dateOfAnswer" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-05T16:30:30.32Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-10-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs: Prices"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the effectiveness of the Intellectual Property Office in helping to keep new drug prices at affordable levels; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "186161"}
    , {"_about" : "http://data.parliament.uk/resources/999387", "AnsweringBody" : [{"_value" : "Ministry of Defence"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/999387/answer", "answerText" : {"_value" : "<p>The top 10 drugs purchased by the Ministry of Defence in each of the last five years by value is as follows:<\/p><p> <\/p><p><strong>2017-18<\/strong><\/p><table><tbody><tr><td><p><strong>Description<\/strong><\/p><\/td><\/tr><tr><td><p>RABIES VACCINE BP SINGLE DOSE VIAL WITH DILUENT WATER FOR INJ 1ML SYRINGE (RAB/VAC) 1 X PK 'RABIPUR'<\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG ATOVAQUONE 250MG F/C TABLETS 1 X 12 PACK<\/p><\/td><\/tr><tr><td><p>MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A,C,Y AND W-135 COMBINED <br> POWDER AND SOLUTION FOR INJECTION INTRAMUSCULAR USE 1 X VIAL WITH 1 X VIAL DILUENT 'MENVEO'<\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE (LIVE) SINGLE DOSE VIAL POWDER FOR INJECTION WITH <br> 0.5ML NACL INJECTION IN SYRINGE 1 X PACK 'STAMARIL'<\/p><\/td><\/tr><tr><td><p>OVER-LABELLED - 12 PROGUANIL/ATOVAQUONE 100/250mg TABLETS-GENERIC<\/p><\/td><\/tr><tr><td><p>ENCEPHALITIS TICK-BORNE VACCINE INACTIVATED 1 X 0.5ML PRELOADED SYRINGE<\/p><\/td><\/tr><tr><td><p>TYPHOID VACCINE POLYSACCARIDE 50MCG/ML SINGLE DOSE 0.5ML PREFILLED <br> SYRINGE 1 X 10 PACK<\/p><\/td><\/tr><tr><td><p>ADALIMUMAB 40MG SOLUTION FOR INJECTION IN 0.4ML PRE-FILLED PEN PACK OF <br> 2 PENS 'HUMIRA'<\/p><\/td><\/tr><tr><td><p>DIPHTHERIA, TETANUS AND PERTUSSIS TOXOID (ACELLULAR) AND HEPATITIS B, <br> POLIOVIRUS AND HAEMOPHILUS TYPE B (HIB) VACCINE PRE-FILLED SYRINGE '<br> INFANRIX HEXA'<\/p><\/td><\/tr><tr><td><p>RABIES VACCINE BP POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION <br> PACK OF 1 VIAL AND 1 PREFILLED SYRINGE 'RABIES BP'<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p><strong>2016-17<\/strong><\/p><table><tbody><tr><td><p><strong>Description<\/strong><\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG ATOVAQUONE 250MG F/C TABLETS 1 X 12 PACK<\/p><\/td><\/tr><tr><td><p>MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A,C,Y AND W-135 COMBINED POWDER AND SOLUTION FOR INJECTION INTRAMUSCULAR USE 1 X VIAL WITH 1 X VIAL DILUENT 'MENVEO'<\/p><\/td><\/tr><tr><td><p>ENCEPHALITIS TICK-BORNE VACCINE INACTIVATED 1 X 0.5ML PRELOADED SYRINGE<\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE (LIVE) SINGLE DOSE VIAL POWDER FOR INJECTION WITH 0.5ML NACL INJECTION IN SYRINGE 1 X PACK 'STAMARIL'<\/p><\/td><\/tr><tr><td><p>RABIES VACCINE BP SINGLE DOSE VIAL WITH DILUENT WATER FOR INJ 1ML SYRINGE (RAB/VAC) 1 X PK 'RABIPUR'<\/p><\/td><\/tr><tr><td><p>HEPATITIS B RECOMBINANT VACCINE ADSORBED 'ENGERIX' 20MCG/ML SUSPENSION FOR INJECTION 1ML PRE-FILLED SYRINGE PACK OF 10<\/p><\/td><\/tr><tr><td><p>ETANERCEPT 50MG PRE-FILLED PEN PACK OF 4<\/p><\/td><\/tr><tr><td><p>FENTANYL CITRATE;LOZENGE;800mcg;LOZENGE w/INTEGRAL OROMUCOSAL APPLICATOR; 1x3<\/p><\/td><\/tr><tr><td><p>HEPATITIS A VIRUS VACCINE INACTIVATED 1ML PFS PACK OF 10 'HAVRIX'<\/p><\/td><\/tr><tr><td><p>PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT ADSORBED) SUSP FOR INJ IN 0.5ML PRE-FILLED SYRINGE PK OF 10 'PREVENAR 13'<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p><strong>2015-16<\/strong><\/p><table><tbody><tr><td><p><strong>Description<\/strong><\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE (LIVE) SINGLE DOSE VIAL POWDER FOR INJECTION WITH 0.5ML NACL INJECTION IN SYRINGE 1 X PACK 'STAMARIL'<\/p><\/td><\/tr><tr><td><p>HEPATITIS B RECOMBINANT VACCINE ADSORBED 'ENGERIX' 20MCG/ML SUSPENSION FOR INJECTION 1ML PRE-FILLED SYRINGE PACK OF 10<\/p><\/td><\/tr><tr><td><p>MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A,C,Y AND W-135 COMBINED POWDER AND SOLUTION FOR INJECTION INTRAMUSCULAR USE 1 X VIAL WITH 1 X VIAL DILUENT 'MENVEO'<\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG ATOVAQUONE 250MG F/C TABLETS 1 X 12 PACK<\/p><\/td><\/tr><tr><td><p>RABIES VACCINE BP SINGLE DOSE VIAL WITH DILUENT WATER FOR INJ 1ML SYRINGE (RAB/VAC) 1 X PK 'RABIPUR'<\/p><\/td><\/tr><tr><td><p>TYPHOID VACCINE POLYSACCARIDE 50MCG/ML SINGLE DOSE 0.5ML PREFILLED SYRINGE 1 X 10 PACK<\/p><\/td><\/tr><tr><td><p>FENTANYL CITRATE;LOZENGE;800mcg;LOZENGE w/INTEGRAL OROMUCOSAL APPLICATOR; 1x3<\/p><\/td><\/tr><tr><td><p>JAPANESE ENCEPHALITIS VACCINE (INACTIVATED, ADSORBED) SUSPENSION FOR INJECTION IN 0.5ML PRE-FILLED SYRINGE IXIARO<\/p><\/td><\/tr><tr><td><p>ETANERCEPT 50MG PRE-FILLED PEN PACK OF 4<\/p><\/td><\/tr><tr><td><p>ENCEPHALITIS TICK-BORNE VACCINE INACTIVATED 1 X 0.5ML PRELOADED SYRINGE<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p><strong>2014-15<\/strong><\/p><table><tbody><tr><td><p><strong>Description<\/strong><\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG ATOVAQUONE 250MG F/C TABLETS 1 X 12 PACK<\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE (LIVE) SINGLE DOSE VIAL POWDER FOR INJECTION WITH 0.5ML NACL INJECTION IN SYRINGE 1 X PACK 'STAMARIL'<\/p><\/td><\/tr><tr><td><p>HEPATITIS B RECOMBINANT VACCINE ADSORBED 'ENGERIX' 20MCG/ML SUSPENSION FOR INJECTION 1ML PRE-FILLED SYRINGE PACK OF 10<\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE 'STAMARIL' (LIVE) UNLICENSED 10 DOSE VIAL PACK OF 10 VIALS (100 DOSE TOTAL)<\/p><\/td><\/tr><tr><td><p>MEFLOQUINE HYDROCHLORIDE 250MG TABLET 1 X 8 PACK<\/p><\/td><\/tr><tr><td><p>RABIES VACCINE BP SINGLE DOSE VIAL WITH DILUENT WATER FOR INJ 1ML SYRINGE (RAB/VAC) 1 X PK 'RABIPUR'<\/p><\/td><\/tr><tr><td><p>MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A,C,Y AND W-135 COMBINED POWDER AND SOLUTION FOR INJECTION INTRAMUSCULAR USE 1 X VIAL WITH 1 X VIAL DILUENT 'MENVEO'<\/p><\/td><\/tr><tr><td><p>PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT ADSORBED) SUSP FOR INJ IN 0.5ML PRE-FILLED SYRINGE PK OF 10 'PREVENAR 13'<\/p><\/td><\/tr><tr><td><p>HEPATITIS A VIRUS VACCINE INACTIVATED 1ML PFS PACK OF 10 'HAVRIX'<\/p><\/td><\/tr><tr><td><p>JAPANESE ENCEPHALITIS VACCINE (INACTIVATED, ADSORBED) SUSPENSION FOR INJECTION IN 0.5ML PRE-FILLED SYRINGE IXIARO<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p><strong>2013-14<\/strong><\/p><table><tbody><tr><td><p><strong>Description<\/strong><\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE (LIVE) SINGLE DOSE VIAL POWDER FOR INJECTION WITH 0.5ML NACL INJECTION IN SYRINGE 1 X PACK 'STAMARIL'<\/p><\/td><\/tr><tr><td><p>HEPATITIS B RECOMBINANT VACCINE ADSORBED 'ENGERIX' 20MCG/ML SUSPENSION FOR INJECTION 1ML PRE-FILLED SYRINGE PACK OF 10<\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG ATOVAQUONE 250MG F/C TABLETS 1 X 12 PACK<\/p><\/td><\/tr><tr><td><p>PROGUANIL HYDROCHLORIDE 100MG TABLETS X 98 AND CHLOROQUINE PHOSPHATE 250MG TABLETS X 14 1 X 112 TABLET TRAVEL PACK<\/p><\/td><\/tr><tr><td><p>MEFLOQUINE HYDROCHLORIDE 250MG TABLET 1 X 8 PACK<\/p><\/td><\/tr><tr><td><p>HEPATITIS A&amp;B VACCINE 'TWINRIX'<\/p><\/td><\/tr><tr><td><p>HEPATITIS B VACCINE 20MCG/ML ADSORBED 1 X 1ML PRE-FILLED SYRINGE<\/p><\/td><\/tr><tr><td><p>HEPATITIS A VACCINE INACTIVATED 1 X PREFILLED SYRINGE<\/p><\/td><\/tr><tr><td><p>MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A,C,Y AND W-135 COMBINED POWDER AND SOLUTION FOR INJECTION INTRAMUSCULAR USE 1 X VIAL WITH 1 X VIAL DILUENT 'MENVEO'<\/p><\/td><\/tr><tr><td><p>YELLOW FEVER VACCINE 'STAMARIL' (LIVE) UNLICENSED 10 DOSE VIAL PACK OF 10 VIALS (100 DOSE TOTAL)<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1487", "label" : {"_value" : "Biography information for Mr Tobias Ellwood"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bournemouth East"}
        , "answeringMemberPrinted" : {"_value" : "Mr Tobias Ellwood"}
        , "dateOfAnswer" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-05T17:04:24.433Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "11"}
      , "answeringDeptShortName" : {"_value" : "Defence"}
      , "answeringDeptSortName" : {"_value" : "Defence"}
      , "date" : {"_value" : "2018-10-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Ministry of Defence: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Defence, if she will publish the top 10 drugs by purchased by his Department in each of the last five years; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "186162"}
    , {"_about" : "http://data.parliament.uk/resources/999389", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/999389/answer", "answerText" : {"_value" : "<p>We are informed by NHS England that in order to ensure the best use of public funds, the National Health Service has used the procurement process to ensure that optimal value for money is achieved when purchasing drugs, which are used in secondary care.<\/p><p> <\/p><p>The NHS is working to ensure consistent use of clinically-appropriate lowest acquisition cost drugs. This has encouraged competitive pricing in return for market share. This process has allowed for an increase in the number of patients being cured within the available resources, with in excess of 30,000 patients with hepatitis C treated so far. The NHS is currently undertaking a long-term strategic procurement to increase treatment and improve value further.<\/p><p> <\/p><p>NHS England\u2019s Commercial Medicines Unit\u2019s six-monthly tenders, together with innovative approaches which mean the NHS is given a refund if a course of treatment does not result in cure, have succeeded in delivering reduced price per patient for all direct acting antiviral Hepatitis C drugs, such as Harvoni (ledipasvir-sofosbuvir).<\/p><p> <\/p><p>The Department has made no such estimate of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access on the grounds of affordability.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "186164"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-05T15:34:31.597Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Harvoni"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the cost to the NHS of Harvoni; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "186163"}
    , {"_about" : "http://data.parliament.uk/resources/999392", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/999392/answer", "answerText" : {"_value" : "<p>We are informed by NHS England that in order to ensure the best use of public funds, the National Health Service has used the procurement process to ensure that optimal value for money is achieved when purchasing drugs, which are used in secondary care.<\/p><p> <\/p><p>The NHS is working to ensure consistent use of clinically-appropriate lowest acquisition cost drugs. This has encouraged competitive pricing in return for market share. This process has allowed for an increase in the number of patients being cured within the available resources, with in excess of 30,000 patients with hepatitis C treated so far. The NHS is currently undertaking a long-term strategic procurement to increase treatment and improve value further.<\/p><p> <\/p><p>NHS England\u2019s Commercial Medicines Unit\u2019s six-monthly tenders, together with innovative approaches which mean the NHS is given a refund if a course of treatment does not result in cure, have succeeded in delivering reduced price per patient for all direct acting antiviral Hepatitis C drugs, such as Harvoni (ledipasvir-sofosbuvir).<\/p><p> <\/p><p>The Department has made no such estimate of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access on the grounds of affordability.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "186163"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-05T15:34:31.66Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Harvoni"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access to the drug on grounds of affordability; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "186164"}
    , {"_about" : "http://data.parliament.uk/resources/997492", "AnsweringBody" : [{"_value" : "Foreign and Commonwealth Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/997492/answer", "answerText" : {"_value" : "<p>I am concerned by the developing political situation in Sri Lanka. I have called on all parties to ensure that the constitution is respected and due political and legal process upheld. The UK urges the President, in consultation with the Speaker, to reconvene parliament immediately to give the democratically elected representatives of the Sri Lankan people their voice. We shall also continue to urge Sri Lanka to implement fully the commitments it has willingly made to the UN Human Rights Council.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1405", "label" : {"_value" : "Biography information for Mark Field"}
        }
        , "answeringMemberConstituency" : {"_value" : "Cities of London and Westminster"}
        , "answeringMemberPrinted" : {"_value" : "Mark Field"}
        , "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-30T16:45:53.027Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "16"}
      , "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"}
      , "date" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sri Lanka: Human Rights"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "What recent steps he has taken to promote human rights in Sri Lanka.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "907365"}
    , {"_about" : "http://data.parliament.uk/resources/984779", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/984779/answer", "answerText" : {"_value" : "<p>In our 2017 Manifesto we committed to safeguarding a Post Office network of at least 11,500 branches and to protect existing rural services. The Government sets the parameters in which the Post Office operates and then allows the Post Office to operate as an independent commercial organisation.<\/p><p>BEIS officials are in regular discussions with the Post Office and continue to monitor the network size.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4487", "label" : {"_value" : "Biography information for Kelly Tolhurst"}
        }
        , "answeringMemberConstituency" : {"_value" : "Rochester and Strood"}
        , "answeringMemberPrinted" : {"_value" : "Kelly Tolhurst"}
        , "dateOfAnswer" : {"_value" : "2018-10-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-23T14:30:13.347Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Post Offices"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what discussions his Department has had with representatives of the Post Office on ensuring the size and accessibility of the branch network.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "177571"}
    , {"_about" : "http://data.parliament.uk/resources/983253", "AnsweringBody" : [{"_value" : "Treasury"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/983253/answer", "answerText" : {"_value" : "<p>HM Treasury has had no discussions with the Australian Government on the proposed Treasury Laws Amendment (Mutual Entities) Bill.<\/p><p> <\/p><p>The Government remains committed to supporting co-operatives, credit unions, building societies and other mutual legal forms as part of a diverse and resilient economy which offers choice to consumers.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"}
        }
        , "answeringMemberConstituency" : {"_value" : "Salisbury"}
        , "answeringMemberPrinted" : {"_value" : "John Glen"}
        , "dateOfAnswer" : {"_value" : "2018-10-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-16T16:03:11.423Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "14"}
      , "answeringDeptShortName" : {"_value" : "Treasury"}
      , "answeringDeptSortName" : {"_value" : "Treasury"}
      , "date" : {"_value" : "2018-10-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mutual Societies: Australia"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Chancellor of the Exchequer, whether he has had discussions with his Australian counterpart on the Australian Government's proposed Treasury Laws Amendment (Mutual Entities) Bill; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "175840"}
    , {"_about" : "http://data.parliament.uk/resources/972424", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/972424/answer", "answerText" : {"_value" : "<p>The Mental Capacity (Amendment) Bill was introduced into Parliament in July 2018 and the Bill has been published on the Parliament website. This implements the Law commission recommendations.<\/p><p> <\/p><p>The Government will provide a response to the Joint Committee of Human Rights report in due time.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "173949"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-09T12:40:20.11Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-09-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mental Capacity"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the Government plans to implement the Law Commission's recommendations with regard to Deprivation of Liberty Safeguards (DoLS) under the Mental Capacity Act 2005; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "173948"}
    , {"_about" : "http://data.parliament.uk/resources/972426", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/972426/answer", "answerText" : {"_value" : "<p>The Mental Capacity (Amendment) Bill was introduced into Parliament in July 2018 and the Bill has been published on the Parliament website. This implements the Law commission recommendations.<\/p><p> <\/p><p>The Government will provide a response to the Joint Committee of Human Rights report in due time.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "173948"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-09T12:40:20.177Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-09-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mental Capacity"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, when he plans to respond to the Joint Committee on Human Rights' inquiry into Deprivation of Liberty Safeguards; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harrow West"}
      , "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
      ], "uin" : "173949"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Gareth+Thomas&_page=1&max-ddpCreated=2018-11-02T15%3A17%3A27.910Z&min-ddpModified=2015-02-06T19%3A13%3A28.727Z", "page" : 0, "startIndex" : 1, "totalResults" : 472, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}